26 MAIN STREET, SUITE 101, CHATHAM, NJ
Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
Investor Presentation
8-K
Reports First Quarter 2026 Financial Results and Operational Highlights
Shareholders Approve 2026 Stock Incentive Plan at Annual Meeting
Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients
Tonix Pharmaceuticals Reports Q1 2026 Financial Results and Cash Position
Q1
Q3
Q2
FY 2024
Notice of Late Filing for Quarterly Report
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Amended Registration Statement for Securities Offered under a Shelf Registration
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload